Debra S. Karhson

TL;DR: Findings indicate that OXT treatment enhances social abilities in children with ASD and that individuals with pretreatment OXT signaling deficits may stand to benefit the most from Oxt treatment.

TL;DR: Preliminary findings suggest that AVP has potential for treating social impairments in children with ASD, and a 4-week intranasal AVP daily treatment was well tolerated with minimal side effects.

TL;DR: These findings are the first empirical human data to translate preclinical rodent findings to confirm a link between plasma anandamide concentrations in children with ASD and suggest that impaired an andamide signaling may be involved in the pathophysiology of ASD.

TL;DR: A role for regulation of gene expression by KChIP3/DREAM/calsenilin in consolidation of contextual fear conditioning memories is suggested.

TL;DR: The empirical evidence reviewed strongly supports the role for dysregulated cannabinoid signaling in the pathophysiology of social functioning deficits observed in brain disorders, such as autism spectrum disorder, schizophrenia, major depressive disorder, posttraumatic stress disorder and bipolar disorder.